Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients.

导出原文传递

翻译打印收藏纠错

作者： Kenji,Morimoto ^[1] ; Tadaaki,Yamada ^[2] ; Ryota,Nakamura ^[1] ; Yuki,Katayama ^[1] ; Satomi,Tanaka ^[1] ; Chieko,Takumi ^[3] ; Noriya,Hiraoka ^[3] ; Yuri,Ogura ^[4] ; Takayuki,Takeda ^[4] ; Keisuke,Onoi ^[5] ; Yusuke,Chihara ^[5] ; Ryusuke,Taniguchi ^[6] ; Takahiro,Yamada ^[6] ; Yohei,Matsui ^[1] ; Osamu,Hiranuma ^[7] ; Yoshie,Morimoto ^[1] ; Masahiro,Iwasaku ^[1] ; Yoshiko,Kaneko ^[1] ; Junji,Uchino ^[1] ; Koichi,Takayama ^[1]

作者单位： Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. ^[1] Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. tayamada@koto.kpu-m.ac.jp. ^[2] Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan. ^[3] Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan. ^[4] Department of Respiratory Medicine, Uji-Tokushukai Medical Center, Kyoto, Japan. ^[5] Department of Pulmonary Medicine, Matsushita Memorial Hospital, Osaka, Japan. ^[6] Department of Pulmonary Medicine, Otsu City Hospital, Shiga, Japan. ^[7]

关键词 Antinuclear antibodies Combinatorial immunotherapy and chemotherapy Immune-related adverse event Non-small cell lung cancer Retrospective analysis